key: cord-1001431-jx40kub3
authors: Focosi, Daniele; Maggi, Fabrizio; McConnell, Scott; Casadevall, Arturo
title: Spike mutations in SARS-CoV-2 AY sublineages of the Delta variant of concern: implications for the future of the pandemic
date: 2022-02-15
journal: Future Microbiol
DOI: 10.2217/fmb-2021-0286
sha: df1ea8b4c365a44c562ce2cac2fa04f0ab491f37
doc_id: 1001431
cord_uid: jx40kub3

nan

Editorial Focosi, Maggi, McConnell & Casadevall is to date the only correlate of immunity and hence the target of neutralizing antibody-based therapeutics (either monoclonal antibodies or convalescent plasma) and preventive vaccines.

Supplementary Table 1 summarizes the 43 AY sublineages (out of 209) harboring Spike mutations, with details on the expected impact of the five sublineages harboring mutations within the Spike receptor-binding domain of subunit S1 (i.e., amino acids 319-541).

Among them, AY.49 has a very interesting mutation, termed Q493E, which has been associated with resistance to both bamlanivimab and etesevimab mAbs [1] [2] [3] . The Q493R mutation emerged during treatment with this cocktail [4] [5] [6] [7] [8] [9] [10] , while Q493K has emerged in a single patient after treatment with casirivimab plus imdevimab [11, 12] . Q493 mutations are exceedingly rare in other SARS-CoV-2 isolates, suggesting selective pressure rather than spontaneous convergent evolution. Similarly, Q493K is one of the founding mutations of the novel Omicron VOC from South Africa (a.k.a. B.1.1.529 or BA.1/BA.2 in PANGOLIN, 21K/21L/21M in NextStrain, GH/484A in GISAID, or VUI-2021-NOV01 in Public Health England).

Of interest, S255F which occurs in AY.106 was also recovered from an immunocompromised host in the absence of neutralizing antibody-based therapeutics [13] , suggesting within-host evolution.

While Delta has clearly outcompeted Alpha and Gamma [14] , Delta is unlikely to be the ultimate SARS-CoV-2 strain. Reports from South Africa, Scotland and Denmark suggest that the Omicron VOC is more transmissive and able to rapidly misplace Delta [15] : whether lockdown and travel restriction will be able to confine Omicron remains unknown, but experience with the former VOCs suggests containment is likely to be futile, especially for a variant that has a higher basic reproduction number. Supplementary Figure 1 shows how the R 0 of SARS-CoV-2 has grown from the original Wuhan strain (2.4-3.4) to Alpha (4) (5) to Delta (5) (6) (7) (8) , and how there is still theoretical room for getting values as high as for measles virus (12) (13) (14) (15) (16) (17) (18) . It can also be expected that with massive circulation Omicron will split into many different sublineages, as it has happened with former VOCs Alpha (eight sublineages), Beta (five sublineages), Gamma (20 sublineages) and Delta (125 sublineages). Even when vaccines inducing sterilizing immunity would become available, the herd immunity threshold could be exceedingly high to be achieved if the elicited immunity is shortlasting.

One of the major lessons from the first 2 years of the pandemic is that in westernized societies modern medicine has saved the lives of millions of individuals at the price of compromised immunity and produced a population of immunocompromised patients who provide vulnerable hosts where SARS-CoV-2 can replicate for prolonged periods of time, resulting in within-host variation. This is an unprecedented landscape for pandemics, which could alter the trajectory of natural evolution. Repeated emergence of Spike variants largely deviating from the originator lineage can hence be anticipated for the coming years, as previously happened for VOCs (Alpha [23 mutations [16] ] and Omicron [32 mutations [15] ]) or lineages that poorly propagated (e.g., A.VOI.V2 [11 Spike mutations [17] ] B.1.1.318 [14 mutations [18] ] and B.1.616 [ten mutations [19] ]), making clear that the number of Spike mutations per se is not a predictor of SARS-CoV-2 fitness.

With mounting evidence suggesting that vaccine efficacy declines significantly after as few as 6 months from the second dose, and considering that sterilizing immunity is not achievable with the current generation of nonmucosal vaccines (leaving room for transmission by vaccines and preventing herd immunity to the immunocompromised nonresponders), sudden and unpredictable Spike evolution calls for urgent research into new different types of vaccines. While it is unclear to date whether whole virus vaccines would provide better correlates of immunity, this is a road that is worth being explored in addition to Spike-only-based vaccines.

Although, the early successes with vaccines and antibody-based therapies in the 1st year of the pandemic gave rise to a premature optimism that the pandemic could be contained in the foreseeable future, it is now clear that humanity might be in for a long struggle with SARS-CoV-2, given its remarkable ability to evolve via single mutations, insertions, deletions or recombination. This is difficult news for COVID-19-weary populations of the world who are entering their 3rd year of the pandemic. However, we believe that public health authorities need to have a frank discussion with the public, admitting the likelihood of the protracted struggle that will see successes, reverses, continued disruption to the norms of everyday life and suffering for many in the form of disease and death. The public in turn needs to be reassured that the way out of this calamity is by continued investment in basic science, clinical research and public health, since the road to normality with an endemic SARS-CoV-2 requires better vaccines and more effective therapies to prevent infection and disease and reduce morbidity and mortality, respectively.

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

SARS-CoV-2 variants in immunocompromised patient given antibody monotherapy

Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient

Emergence of E484K mutation following bamlanivimab monotherapy among high-risk patients infected with the alpha variant of SARS-CoV-2

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance

Influence of neutralizing monoclonal antibodies on the SARS-CoV-2 quasispecies in patients with COVID-19

Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

Emergence of SARS-CoV-2 spike escape mutation Q493R after treatment for COVID-19

Persistence and evolution of SARS-CoV-2 in an immunocompromised host

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual

The SARS-CoV-2 variant Delta displaced the variants Gamma and Gamma plus in Amazonas

SARS-CoV-2 variants of concern and variants under investigation in England

Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70

A novel variant of interest of SARS-CoV-2 with multiple spike mutations is identified from travel surveillance in Africa

A novel and expanding SARS-CoV-2 variant, B.1.1.318, dominates infections in Mauritius

A new SARS-CoV-2 variant poorly detected by RT-PCR on nasopharyngeal samples, with high lethality